$ANIX

Titterton Lewis H jr purchased $7K of ANIX

Titterton Lewis H jr purchased 2,836 shares of Anixa Biosciences Inc (ANIX) at $2.64 on 2026-06-16.

Original reporting
SEC EDGAR · Titterton Lewis H jr
Published Jun 17, 2026, 3:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 3:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ANIX
Bullish
low confidence
Mentioned
$ANIX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (shares, price, total value) disclosed on 2026-06-17 for a trade dated 2026-06-16.

02

Market read

Traders may treat the filing as a small sentiment input, but it does not provide new fundamentals or guidance.

03

What to watch

Check whether the director has a history of buys/sells and whether there are concurrent corporate events (financing, trial updates) not mentioned here.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-17; transaction dated 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure for Anixa Biosciences (ANIX).

Company-level read

Ticker impact

$ANIXBullishLow confidence
Context

Anixa Biosciences director Titterton Lewis H jr filed a Form 4 open-market purchase of 2,836 shares at $2.6400 on 2026-06-16.

Expected impact

Near-term impact likely limited; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The disclosure is a routine Form 4 insider purchase with no new operational/financial catalyst, and the transaction size is small relative to typical market-moving thresholds.

Market effects

Minimal; single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary and may not reflect a durable thesis; without a 10b5-1 plan, timing could be opportunistic rather than informational.

Key entities

  • Anixa Biosciences Inc

    Subject of the Form 4 insider transaction disclosure.

  • Titterton Lewis H jr

    Director who reported an open-market purchase of ANIX shares.

Related articles